KCA
Search
- Page Path
- HOME > Search
Original Article
- Gastrointestinal cancer
- Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma
- Se Jin Choi, Sung Won Chung, Jonggi Choi, Kang Mo Kim, Hyung-Don Kim, Changhoon Yoo, Baek-Yeol Ryoo, Seung Soo Lee, Won-Mook Choi, Sang Hyun Choi
- Cancer Res Treat. 2024;56(4):1219-1230. Published online May 7, 2024
- DOI: https://doi.org/10.4143/crt.2024.283
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
This study aimed to identify clinical and radiologic characteristics that could predict response to atezolizumab-bevacizumab combination therapy in patients with advanced hepatocellular carcinoma (HCC).
Materials and Methods
This single-center retrospective study included 108 advanced HCC patients with intrahepatic lesions who were treated with atezolizumab-bevacizumab. Two radiologists independently analyzed imaging characteristics of the index tumor on pretreatment computed tomography. Predictive factors associated with progressive disease (PD) at the best response based on Response Evaluation Criteria in Solid Tumors, ver. 1.1 were evaluated using logistic regression analysis. Progression-free survival (PFS) was estimated by the Kaplan-Meier method and compared with the log-rank test.
Results
Of 108 patients with a median PFS of 15 weeks, 40 (37.0%) had PD during treatment. Factors associated with PD included the presence of extrahepatic metastases (adjusted odds ratio [aOR], 4.13; 95% confidence interval [CI], 1.19 to 14.35; p=0.03), the infiltrative appearance of the tumor (aOR, 3.07; 95% CI, 1.05 to 8.93; p=0.04), and the absence of arterial-phase hyperenhancement (APHE) (aOR, 6.34; 95% CI, 2.18 to 18.47; p < 0.001). Patients with two or more of these factors had a PD of 66.7% and a median PFS of 8 weeks, indicating a significantly worse outcome compared to the patients with one or no of these factors.
Conclusion
In patients with advanced HCC treated with atezolizumab-bevacizumab treatment, the absence of APHE, infiltrative appearance of the intrahepatic tumor, and presence of extrahepatic metastases were associated with poor response and survival. Evaluation of early response may be necessary in patients with these factors. -
Citations
Citations to this article as recorded by
- Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features
Won Suk Lee, Seonjeong Woo, Sung Hwan Lee, Gae Hoon Jo, Ilhwan Kim, Hyeyeong Kim, Chansik An, Sanghoon Jung, Gwangil Kim, Haeyoun Kang, Beodeul Kang, Jung Sun Kim, Ho Yeong Lim, Incheon Kang, Hannah Yang, So Jung Kong, Dahyeon Son, Dong Jun Shin, Woo Youn
Clinical and Molecular Hepatology.2026; 32(1): 258. CrossRef - Transarterial chemoembolization combined with immune checkpoint inhibitors and anti-VEGF agents for intermediate HCC: a multicenter study
Wei-Yi Jiang, Jin-Kai Feng, Bin Zhou, Si-Si Ren, Yu-Chao Hou, Fang-Fang Zhang, Yan-Jun Xiang, Zong-Han Liu, Rong-Chen Chen, Yun-Feng Shan, Chao Liang, Hong-Kun Zhou, Lin Gong, Shu-Qun Cheng
European Journal of Surgical Oncology.2026; 52(3): 111407. CrossRef - Significance of Measuring Interferon-γ-Induced Protein-10 Levels in Patients Receiving Systemic Therapies for Unresectable Hepatocellular Carcinoma
Hitomi Takada, Leona Osawa, Yasuyuki Komiyama, Masaru Muraoka, Yuichiro Suzuki, Mitsuaki Sato, Shoji Kobayashi, Takashi Yoshida, Shinichi Takano, Shinya Maekawa, Atsunori Tsuchiya, Nobuyuki Enomoto
Oncology.2026; : 1. CrossRef - Current and Emerging Immunotherapy Strategies in Hepatocellular Carcinoma: Standard Treatments and Biomarkers
Yoonseok Lee
Journal of Digestive Cancer Research.2026; 14(1): 53. CrossRef - Application of imaging modalities in predicting and evaluating response to anti-vascular endothelial growth factor agents and immune checkpoint inhibitors in patients with hepatocellular carcinoma
Li-Ping Zhou, Wei Yang
World Chinese Journal of Digestology.2025; 33(6): 441. CrossRef - Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Kiyoyuki Minamiguchi, Mariko Irizato, Ryota Nakano, Hideki Kunichika, Tetsuya Tachiiri, Ryosuke Taiji, Yuki Tsuji, Satoshi Yasuda, Hitoshi Yoshiji, Masayuki Sho, Toshihiro Tanaka
Current Oncology.2025; 32(12): 694. CrossRef - Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence
María Martínez Burgos, Rocío González Grande, Susana López Ortega, Inmaculada Santaella Leiva, Jesús de la Cruz Lombardo, Julio Santoyo Santoyo, Miguel Jiménez Pérez
Biomedicines.2024; 12(6): 1302. CrossRef
- Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features
- 4,786 View
- 178 Download
- 5 Web of Science
- 7 Crossref
First
Prev
